text
"['\n1. 요약재무정보\n당사는 2018년 9월 19일 발표된 [제약ㆍ바이오 기업의 연구개발비 회계처리 관련 감독지침]을 고려, 개발비 자산화 시점의 회계처리 오류(무형자산 과대계상 및 경상연구개발비 과소계상 등)를 수정하였으며, 이에 따라 제28기(전전기) 재무재표는 소급 재작성되었습니다\n가. 요약연결재무정보\n(단위: 원)\n구 분\n제30기\n제29기\n제28기\n(2020년 12월말)\n(2019년 12월말)\n(2018년 12월말)\n[유동자산]\n2,516,494,911,747\n1,785,115,919,500\n1,664,281,326,370\n\xa0ㆍ현금및현금성자산\n684,293,887,404\n546,137,583,490\n410,547,608,852\n\xa0ㆍ단기금융자산\n14,034,380,800\n81,681,590,783\n121,636,304,845\n\xa0ㆍ매출채권\n1,252,394,564,236\n814,370,251,982\n807,711,314,915\n\xa0ㆍ기타수취채권\n63,321,890,588\n12,372,205,267\n124,267,624,254\n\xa0ㆍ재고자산\n384,324,660,641\n306,709,922,768\n162,916,820,624\n\xa0ㆍ당기법인세자산\n-\n-\n9,523,563,778\n\xa0ㆍ기타유동자산\n118,125,528,078\n23,844,365,210\n27,678,089,102\n[비유동자산]\n2,503,626,342,272\n2,074,530,709,558\n1,838,826,878,560\n\xa0ㆍ장기금융자산\n31,346,052,415\n17,629,052,511\n18,989,084,041\n\xa0ㆍ장기기타수취채권\n10,138,443,975\n10,733,643,020\n10,287,886,409\n\xa0ㆍ관계기업투자\n48,026,573,643\n47,841,529,392\n28,003,078,925\n\xa0ㆍ유형자산\n946,280,260,465\n923,592,891,742\n881,437,749,875\n\xa0ㆍ무형자산\n1,404,188,585,515\n1,008,192,903,389\n885,018,659,777\n\xa0ㆍ기타비유동자산\n34,658,542,248\n43,229,409,217\n15,090,419,533\n\xa0ㆍ이연법인세자산\n28,987,884,011\n23,311,280,287\n-\n자산총계\n5,020,121,254,019\n3,859,646,629,058\n3,503,108,204,930\n[유동부채]\n1,056,766,920,798\n657,225,837,904\n678,087,471,395\n[비유동부채]\n535,773,979,083\n329,507,580,221\n229,761,340,951\n부채총계\n1,592,540,899,881\n986,733,418,125\n907,848,812,346\n[자본금]\n134,997,805,000\n128,337,853,000\n125,456,133,000\n[주식발행초과금]\n812,155,732,299\n786,358,490,538\n761,047,500,208\n[이익잉여금]\n2,475,296,679,338\n1,963,727,518,268\n1,665,189,222,641\n[기타포괄손익누계액]\n6,298,419,403\n3,000,227,548\n9,970,124,880\n[기타자본항목]\n(121,071,590,883)\n(121,314,726,197)\n(75,159,128,990)\n[비지배지분]\n119,903,308,981\n112,803,847,776\n108,755,540,845\n자본총계\n3,427,580,354,138\n2,872,913,210,933\n2,595,259,392,584\n(2020.01.01~2020.12.31)\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n매출액\n1,849,115,532,111\n1,128,459,877,886\n982,074,959,799\n영업이익\n718,577,359,816\n381,532,472,575\n323,131,558,365\n법인세비용차감전순이익\n657,152,015,874\n382,031,278,440\n301,639,078,511\n당기순이익\n525,702,909,620\n301,442,694,249\n237,476,360,558\n\xa0ㆍ지배기업소유주지분\n517,759,533,401\n301,030,346,627\n245,755,018,366\n\xa0ㆍ비지배지분\n7,943,376,219\n412,347,622\n(8,278,657,808)\n\xa0ㆍ기본주당이익\n3,873\n2,255\n1,840\n연결에 포함된 회사수\n10\n10\xa0\n8\xa0\n나. 요약재무정보\n(단위: 원)\n구 분\n제30기\n제29기\n제28기\n(2020년 12월말)\n(2019년 12월말)\n(2018년 12월말)\n[유동자산]\n2,294,204,328,641\n1,610,730,917,459\n1,482,310,007,849\n\xa0ㆍ현금및현금성자산\n615,216,683,989\n526,092,843,365\xa0\n399,558,425,745\n\xa0ㆍ단기금융자산\n10,034,380,800\n79,113,846,512\xa0\n121,636,304,845\n\xa0ㆍ매출채권\n1,139,308,334,817\n690,252,563,176\xa0\n689,472,264,429\n\xa0ㆍ기타수취채권\n81,332,323,881\n25,476,236,632\xa0\n123,885,214,981\n\xa0ㆍ재고자산\n333,901,355,140\n268,715,675,450\n125,717,441,514\n\xa0ㆍ기타유동자산\n114,411,250,014\n21,079,752,324\xa0\n22,040,356,335\n[비유동자산]\n2,486,920,960,591\n2,063,791,784,809\n1,888,329,253,915\n\xa0ㆍ장기금융자산\n30,413,459,273\n15,406,459,369\xa0\n17,407,490,899\n\xa0ㆍ장기기타수취채권\n16,138,373,036\n9,618,771,557\xa0\n9,141,484,165\n\xa0ㆍ종속기업및관계기업투자\n631,938,696,277\n313,849,033,448\xa0\n286,212,166,532\n\xa0ㆍ유형자산\n695,641,290,578\n701,428,195,334\xa0\n677,870,722,592\n\xa0ㆍ무형자산\n1,088,436,038,129\n987,732,187,355\n877,141,249,708\n\xa0ㆍ투자부동산\n-\n2,918,466,663\xa0\n5,982,493,446\n\xa0ㆍ기타비유동자산\n24,353,103,298\n32,838,671,083\xa0\n14,573,646,573\n자산총계\n4,781,125,289,232\n3,674,522,702,268\n3,370,639,261,764\n[유동부채]\n900,571,681,471\n517,564,388,814\n548,121,290,075\n[비유동부채]\n459,265,660,740\n286,291,312,657\n218,455,704,094\n부채총계\n1,359,837,342,211\n803,855,701,471\n766,576,994,169\n[자본금]\n134,997,805,000\n128,337,853,000\xa0\n125,456,133,000\n[주식발행초과금]\n812,155,732,299\n786,358,490,538\xa0\n761,047,500,208\n[이익잉여금]\n2,588,503,365,521\n2,080,593,620,747\n1,793,330,987,094\n[기타포괄손익누계액]\n13,208,899,479\n2,590,862,595\xa0\n5,011,173,208\n[기타자본항목]\n(127,577,855,278)\n(127,213,826,083)\n(80,783,525,915)\n자본총계\n3,421,287,947,021\n2,870,667,000,797\n2,604,062,267,595\n종속ㆍ관계ㆍ공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n(2020.01.01~2020.12.31)\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n매출액\n1,689,786,996,813\n981,870,268,852\n861,884,226,306\n영업이익\n709,774,140,131\n363,391,097,232\n319,413,201,208\n법인세비용차감전순이익\n649,888,873,280\n369,106,504,865\n296,187,867,991\n당기순이익\n514,270,057,774\n289,754,684,653\n238,274,199,791\n\xa0ㆍ기본주당이익\n3,847\n2,170\n1,784\n']"
